Drug policy in China. Transformations, current status and future prospects

PharmacoEconomics

Volumn 12, Issue 1, 1997, Pages 1-9

  Liu, Xingzhu ^a   Li, Shixue ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG;

ARTICLE; CHINA; COST CONTROL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MISUSE; DRUG USE; ECONOMIC ASPECT; GOVERNMENT; HEALTH CARE NEED; HEALTH INSURANCE; HUMAN; MARKET; PHARMACOECONOMICS; POLICY; PRIORITY JOURNAL;

EID: 0030753631     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712010-00001     Document Type: Article

References (27)

1. Guo WY, Gueng JW. The development of the pharmaceutical market and its prospect in Shanxi Province. Pharm Info 1989; (2): 30-3
2. Xing ML. The discussion of pharmaceutical technology. Pharm Info 1985; (1): 1-9
3. Guo J, Wang ZG. An introduction to the selection of essential drug list in China. Chin Pharm 1995; 6 (2): 4-6
4. Li Q. The prospects of the Chinese pharmaceutical market in 1996. Chin Pharm Info 1996; 2(1): 30-7
5. Shang HW. Adapting to the market economy and strengthening the macro-management. Chin Pharm Info 1995; 1 (6): 335-9
6. Zheng CZ. The study of Chinese pharmaceutical administration model. J Chin Med Info 1996; 3 (2): 3-6
7. Guo FW. The simple methods of prediction for pharmaceutical markets. Chin Pharm Info 1996; 2 (1): 15-21
8. Chen WX. The development tendency of the Chinese pharmaceutical market. Chin Pharm 1995; 6 (4): 2-3
9. Dong D. A discussion about discount of drug prices. Shanghai J Med 1996; (1): 7-8
10. Shun CZ. The current status and basic principles of drugs importation. Chin Pharm 1996; 7 (1): 3-4
11. Zhang WK. The further improvement of drugs administration and inspection. Chin Pharm 1995; 6 (1): 3-6
12. Zhen XS. The prospect of Chinese pharmaceutical industries. Health Econ Res. In press
13. Li SJ. The development of joint venture pharmaceutical industries. Chin Pharm Info 1995; 1 (5): 274-5
14. Liu ZG. The problems of administration of hospital drugs. Shanghai J Med 1996; (2): 32-33
15. Shan HQ. The protection of state-owned industries benefit rights. Chin Pharm Info 1995; 1 (3): 136-8
16. Mao JW, Xue M. The analysis of financial status of hospitals in 1994. Chin J Hosp Manag 1995; 15 (8): 5-9
17. Liu XZ, Hsiao WC. The cost escalation of social health insurance plans in China: its implication for public policy. Soc Sci Med 1995; 41 (8): 1095-101
18. Wang SC, Xie FS. The current problems and suggestions for drugs inspection. Chin Pharm 1996; 7 (2): 57-8
19. Peng L, Wang HM. The vicious increase of health expenditure should be contained. Chin Health Pol 1996; (2): 21-2
20. The Digest of Health Statistics. Beijing, People's Republic of China: Ministry of Health, 1995
21. Lei HC, Liu XZ. The prediction to the change of prevalence rate of chronic disease. Chin Health Econ 1996; 15 (10): 7-9
22. Lei HC, Liu XZ. The prediction of medical expenditure on chronic diseases. Chin Health Econ 1996; 15 (10): 18-9
23. Chen JY. Exploring the trend of pharmaceutical market in 1995. Cin Pharm Inf 1995; 1 (2): 84-6
24. Cai RH. Evaluation of pilot reform of social health insurance. Reg Health Plan 1995 (8): 33-7
25. Chen W, Cheng XM, Li JM, et al. The study of the impact of positive list of drugs coverage on hospital use of drugs. Chin Hosp Manag 1995; 15 (7): 8-11
26. Zhen SZ, Wang JF, Wang LX. The benefit analysis of 'revenue control and structure adjustment' policy. Chin J Hosp Adm 1995; 11 (9): 524-5
27. Zhou HY, Wang LX, Shun RC. The affection to pharmaceutical industries by the 'revenue control and structure adjustment' policy. Chin J Hosp Adm 1995; 11 (9): 534-6